Reduced oral itraconazole bioavailability by antacid suspension.

Reduced oral itraconazole bioavailability by antacid suspension.

Item
http://www.wikidata.org/entity/Q46492452
Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states.Safety of triazole antifungal drugs in patients with cancer.Clinically significant drug interactions with antacids: an update.Azole interactions with multidrug therapy in pediatric oncology.Pharmacokinetic considerations in treating invasive pediatric fungal infections.Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children.Prediction of area under the curve for a p-glycoprotein, a CYP3A4 and a CYP2C9 substrate using a single time point strategy: assessment using fexofenadine, itraconazole and losartan and metabolites.Potential drug-drug interactions in cardiothoracic intensive care unit of a pulmonary teaching hospital.
P2860

Reduced oral itraconazole bioavailability by antacid suspension.

Item
http://www.wikidata.org/entity/Q46492452
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Reduced oral itraconazole bioavailability by antacid suspension.
@en
Reduced oral itraconazole bioavailability by antacid suspension.
@nl
type
label
Reduced oral itraconazole bioavailability by antacid suspension.
@en
Reduced oral itraconazole bioavailability by antacid suspension.
@nl
prefLabel
Reduced oral itraconazole bioavailability by antacid suspension.
@en
Reduced oral itraconazole bioavailability by antacid suspension.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
Reduced oral itraconazole bioavailability by antacid suspension.
@en
P2093
P2860
P304
P31
P356
10.1111/J.1365-2710.2005.00632.X
P433
P478
P577
P698